Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial

NCT ID: NCT05554406Sponsor: National Cancer Institute (NCI)Last updated: 2026-06-17

Summary

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.

Detailed description

PRIMARY OBJECTIVE: I. To compare measurable residual disease (MRD) negative complete remission (CR) rates between each of the experimental regimens and cytarabine + daunorubicin (7+3). SECONDARY OBJECTIVES: I. To estimate the frequency and severity of toxicities with each of the regimens. II. To estimate complete remission (CR) rates, complete remission with incomplete count recovery (CRi, with and without MRD) rates, event-free survival (EFS), time to relapse, relapse-free survival (RFS), and overall survival (OS) with each of the regimens. III. To describe and compare MRD negative CR rates by genomic subgroups within and across randomized arms. BANKING OBJECTIVE: I. To bank specimens for future correlative studies. OUTLINE: Patients are randomized to 1 of 5 arms. ARM I: Patients receive cytarabine intravenously (IV) continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo echocardiography (ECHO) or multigated acquisition (MUGA) scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. ARM II: Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax orally (PO) on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. ARM III: Patients receive azacitidine subcutaneously (SC) or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. ARM IV: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. ARM V: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. After completion of study treatment, patients follow up every month for the first year, every 2 months for the second year, every 3 months for the third year and every 6 months to year 5.

Arms & interventions

  • DrugAzacitidine

    Given SC or IV

  • ProcedureBiospecimen Collection

    Undergo collection of blood

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • DrugCytarabine

    Given IV

  • DrugDaunorubicin Hydrochloride

    Given IV

  • ProcedureEchocardiography Test

    Undergo ECHO

  • DrugLiposome-encapsulated Daunorubicin-Cytarabine

    Given IV

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA

  • DrugVenetoclax

    Given PO

Outcome measures

Primary

  • Minimal residual disease (MRD) response (Arm 1, 2, 4 and 5)

    Will be analyzed using intent-to-treat (ITT) principles.

    Time frame: After induction (28 days) or re-induction (56 days)

  • MRD response (Arm 3)

    Will be analyzed using ITT principles.

    Time frame: After two cycles of therapy (56 days)

Secondary

  • Early mortality

    Time frame: On or before day 28

  • Time to count recovery

    Time frame: After cycle 1 and cycle 2

  • Event-free survival

    Time frame: From randomization to the first of: primary refractory disease; progressive disease; off protocol therapy without complete remission (CR) or CR with incomplete count recovery (CRi); relapse from CR or CRi, or death from any cause, assessed up to 5 years

  • Relapse-free survival

    Time frame: From the date of achievement of a remission until the date of relapse or death from any cause, assessed up to 5 years

  • Overall survival

    Time frame: From day of randomization on study until death from any cause, assessed up to 5 years

  • Time to relapse

    Time frame: Up to 5 years

  • MRD negative complete remission (MRDneg CR)

    Time frame: Up to 5 years

  • Incidence of adverse events

    Time frame: Up to 5 years

Eligibility criteria

Sex: AllAge: 18 Years to 59 YearsHealthy volunteers: No
Inclusion Criteria: * STEP 1 REGISTRATION: * Participants must have been registered to Master Screening and Re-Assessment Protocol, MYELOMATCH, prior to consenting to this study. Participants must have been assigned to this clinical trial, via MATCHBox, prior to registration to this study. * Note: Pre-enrollment/diagnosis labs must have already been performed under MYELOMATCH * Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) per World Health Organization (WHO) criteria * Participants must have high-risk (adverse) AML per European LeukemiaNet (ELN) 2017 criteria * Participants with therapy-related AML (t-AML), or with AML evolving from an antecedent hematologic disorder (such as myeloproliferative neoplasm), or AML with myelodysplasia-related changes (AML-MRC) are eligible * Acute promyelocytic leukemia is excluded * Participants with favorable or intermediate risk disease are excluded * Participants with FLT3 mutations (ITD or TKD) are excluded * Participants with t(9;22) translocation are excluded * A single dose of intrathecal chemotherapy is allowed prior to study entry * Prior anthracycline therapy is allowed but must not exceed a cumulative lifetime dose of 200 mg/m\^2 daunorubicin or equivalent. Prior hypomethylating agent (HMA) exposure is allowed, as long as not for AML diagnosis * Participants must not have received or be currently receiving any prior therapy for acute myeloid leukemia. Hydroxyurea to control the white blood cells (WBC) is allowed prior to registration and initiation of protocol-defined therapy. All trans retinoic acid (ATRA) given until a diagnosis of acute promyelocytic leukemia is ruled out is also allowed. * Participants must not be receiving or planning to receive any other investigational agents before completing protocol therapy * Participants must be between 18 and 59 years of age * Participants must have Zubrod performance status =\< 3 as determined by a history and physical (H\&P) completed within 14 days prior to registration * Participants must have a complete medical history and physical exam within 7 days prior to registration * Participants must be able to swallow and retain oral medications and have no known gastrointestinal disorders likely to interfere with absorption of oral medications * Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months prior to registration * Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load within 28 days prior to registration and be on suppressive therapy, if indicated * Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load within 28 days prior to registration * The following tests must be performed within 14 days prior to registration to establish baseline values: * Complete blood count (CBC)/differential/platelets * Total bilirubin * Lactate dehydrogenase (LDH) * Albumin * Glucose * Fibrinogen * Participants must have adequate kidney function as evidenced by creatinine clearance \>= 30mL/min (by Cockcroft Gault) within 28 days prior to registration * Participants must have adequate liver function as evidenced by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3.0 x upper limit of normal (ULN) within 28 days prior to registration * Total bilirubin =\< 2.0 x ULN (or 5.0 x ULN if the participant has a history of Gilbert's disease) within 28 days prior to registration * Participants must have adequate cardiac function as determined by echocardiography or MUGA scan with an ejection fraction \>= 50% within 28 days prior to registration * Participants with a prior or concurrent malignancy whose natural history (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. No concurrent therapies for such malignancy are allowed with the exception of hormonal therapy * Participants with known history of Wilson's disease or other known copper-metabolism disorder are excluded * Participants must not be pregnant or nursing. Women/men of reproductive potential must have agreed to use 2 contraception methods. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods (e.g., hormonal contraceptives \[examples include birth control pills, vaginal rings, or patches\] associated with inhibition of ovulation for at least 1 month prior to taking study drug), "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. A barrier method should be used during this study along with hormonal contraceptives from initial study drug administration to 30 days after the last dose of study drug as drug-drug interaction with venetoclax is unknown * Participants must have agreed to have specimens submitted for translational medicine (MRD) under the myeloMATCH MSRP and specimens must be submitted * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines * As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

Study locations (211)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233

Recruiting
Site Public Contact · Contact
gingerreeves@uabmc.edu
Razan Mohty · Principal Investigator

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054

Recruiting
Site Public Contact · Contact
855-776-0015
Antoine Saliba · Principal Investigator

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Sharad Khurana · Principal Investigator

University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Sharad Khurana · Principal Investigator

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205

Recruiting
Site Public Contact · Contact
501-686-8274
Ankur Varma · Principal Investigator

Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, 94704

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Ari D. Baron · Principal Investigator

Cedars-Sinai Medical Center

Los Angeles, California, 90048

Recruiting
Site Public Contact · Contact
310-423-2133Cancer.trial.info@cshs.org
Noah M. Merin · Principal Investigator

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817

Recruiting
Site Public Contact · Contact
916-734-3089
Brian A. Jonas · Principal Investigator

UCSF Medical Center-Parnassus

San Francisco, California, 94143

Recruiting
Site Public Contact · Contact
877-827-3222
Timothy Ferng · Principal Investigator

Mills Health Center

San Mateo, California, 94401

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Ari D. Baron · Principal Investigator

Yale University

New Haven, Connecticut, 06520

Recruiting
Site Public Contact · Contact
203-785-5702canceranswers@yale.edu
Jan P. Bewersdorf · Principal Investigator

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980

Recruiting
Site Public Contact · Contact
855-776-0015
Antoine Saliba · Principal Investigator

Miami Cancer Institute

Miami, Florida, 33176

Recruiting
Site Public Contact · Contact
786-596-2000
Firas El Chaer · Principal Investigator

Memorial Hospital West

Pembroke Pines, Florida, 33028

Recruiting
Site Public Contact · Contact
954-265-4325
Jonathan Feld · Principal Investigator

Phoebe Putney Memorial Hospital

Albany, Georgia, 31701

Recruiting
Site Public Contact · Contact
229-312-0405ga_cares@augusta.edu
Vamsi Kota · Principal Investigator

Augusta University Medical Center

Augusta, Georgia, 30912

Recruiting
Site Public Contact · Contact
706-721-2388ga_cares@augusta.edu
Vamsi Kota · Principal Investigator

Hawaii Cancer Care Inc - Waterfront Plaza

Honolulu, Hawaii, 96813

Recruiting
Site Public Contact · Contact
808-524-6115i.webster@hawaiicancercare.com
Craig S. Boddy · Principal Investigator

Straub Clinic and Hospital

Honolulu, Hawaii, 96813

Recruiting
Site Public Contact · Contact
808-522-4333
Craig S. Boddy · Principal Investigator

Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, 96826

Recruiting
Site Public Contact · Contact
808-983-6090
Craig S. Boddy · Principal Investigator

Hawaii Cancer Care - Westridge

‘Aiea, Hawaii, 96701

Recruiting
Site Public Contact · Contact
808-539-2273info@hawaiicancercare.com
Craig S. Boddy · Principal Investigator

Pali Momi Medical Center

‘Aiea, Hawaii, 96701

Recruiting
Site Public Contact · Contact
808-486-6000
Craig S. Boddy · Principal Investigator

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Tareq Al baghdadi · Principal Investigator

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Charles W. Drescher · Principal Investigator

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

OSF Saint Joseph Medical Center

Bloomington, Illinois, 61701

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Canton

Canton, Illinois, 61520

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Carthage

Carthage, Illinois, 62321

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Northwestern University

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
312-695-1301cancer@northwestern.edu
Jessica K. Altman · Principal Investigator

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Dixon

Dixon, Illinois, 61021

Recruiting
Site Public Contact · Contact
815-285-7800
Bryan A. Faller · Principal Investigator

Crossroads Cancer Center

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Eureka

Eureka, Illinois, 61530

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201

Recruiting
Site Public Contact · Contact
847-570-2109
David L. Grinblatt · Principal Investigator

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

NorthShore University HealthSystem-Glenbrook Hospital

Glenview, Illinois, 60026

Recruiting
Site Public Contact · Contact
847-570-2109
David L. Grinblatt · Principal Investigator

NorthShore University HealthSystem-Highland Park Hospital

Highland Park, Illinois, 60035

Recruiting
Site Public Contact · Contact
847-570-2109
David L. Grinblatt · Principal Investigator

Illinois CancerCare-Kewanee Clinic

Kewanee, Illinois, 61443

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Macomb

Macomb, Illinois, 61455

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Loyola University Medical Center

Maywood, Illinois, 60153

Recruiting
Site Public Contact · Contact
708-226-4357
Stephanie B. Tsai · Principal Investigator

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Methodist Medical Center of Illinois

Peoria, Illinois, 61636

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

OSF Saint Francis Medical Center

Peoria, Illinois, 61637

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peru

Peru, Illinois, 61354

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Princeton

Princeton, Illinois, 61356

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare - Washington

Washington, Illinois, 61571

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

UChicago Medicine Northwest Indiana

Crown Point, Indiana, 46307

Recruiting
Site Public Contact · Contact
855-702-8222cancerclinicaltrials@bsd.uchicago.edu
Olatoyosi M. Odenike · Principal Investigator

Indiana University/Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202

Recruiting
Site Public Contact · Contact
317-278-5632iutrials@iu.edu
Rita Assi · Principal Investigator

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242

Recruiting
Site Public Contact · Contact
800-237-1225
Prajwal Dhakal · Principal Investigator

University of Kansas Clinical Research Center

Fairway, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Tara L. Lin · Principal Investigator

University of Kansas Cancer Center

Kansas City, Kansas, 66160

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Tara L. Lin · Principal Investigator

University of Kansas Hospital-Indian Creek Campus

Overland Park, Kansas, 66211

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Tara L. Lin · Principal Investigator

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Tara L. Lin · Principal Investigator

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Recruiting
Site Public Contact · Contact
859-257-3379
Ayman Qasrawi · Principal Investigator

The James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, 40202

Recruiting
Site Public Contact · Contact
502-562-3429
Mohamed M. Hegazi · Principal Investigator

UofL Health Medical Center Northeast

Louisville, Kentucky, 40245

Recruiting
Site Public Contact · Contact
502-852-2755ctoinfo@louisville.edu
Mohamed M. Hegazi · Principal Investigator

LSU Health Baton Rouge-North Clinic

Baton Rouge, Louisiana, 70805

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Harry G. Sequeira Gross · Principal Investigator

Our Lady of the Lake Physician Group

Baton Rouge, Louisiana, 70808

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Harry G. Sequeira Gross · Principal Investigator

Our Lady of The Lake

Baton Rouge, Louisiana, 70808

Recruiting
Site Public Contact · Contact
225-765-7659
Harry G. Sequeira Gross · Principal Investigator

MaineHealth Maine Medical Center - Portland

Portland, Maine, 04102

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

MaineHealth Maine Medical Center- Scarborough

Scarborough, Maine, 04074

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

MaineHealth Cancer Care and IV Therapy - South Portland

South Portland, Maine, 04106

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Pamela Egan · Principal Investigator

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287

Recruiting
Site Public Contact · Contact
410-955-8804jhcccro@jhmi.edu
Alexander J. Ambinder · Principal Investigator

Walter Reed National Military Medical Center

Bethesda, Maryland, 20889-5600

Recruiting
Site Public Contact · Contact
301-319-2100
Ryan Jones · Principal Investigator

Tufts Medical Center

Boston, Massachusetts, 02111

Recruiting
Site Public Contact · Contact
617-636-5000ContactUsCancerCenter@TuftsMedicalCenter.org
Andreas K. Klein · Principal Investigator

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215

Recruiting
Site Public Contact · Contact
617-667-9925
Malgorzata McMasters · Principal Investigator

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Recruiting
Site Public Contact · Contact
877-442-3324
Eric S. Winer · Principal Investigator

Lahey Hospital and Medical Center

Burlington, Massachusetts, 01805

Recruiting
Site Public Contact · Contact
781-744-3421lhmc-cancer-clinical-trials@lahey.org
Hossein Sadrzadeh · Principal Investigator

Lahey Clinic Peabody

Peabody, Massachusetts, 01960

Recruiting
Site Public Contact · Contact
781-744-3421lhmc-cancer-clinical-trials@lahey.org
Hossein Sadrzadeh · Principal Investigator

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Macomb Hospital-Clinton Township

Clinton Township, Michigan, 48038

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201

Recruiting
Site Public Contact · Contact
800-527-6266ctoadmin@karmanos.org
Vijendra Singh · Principal Investigator

Henry Ford Hospital

Detroit, Michigan, 48202

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Vijendra Singh · Principal Investigator

Cancer Hematology Centers - Flint

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Tareq Al baghdadi · Principal Investigator

Genesee Hematology Oncology PC

Flint, Michigan, 48503

Suspended

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Tareq Al baghdadi · Principal Investigator

Hurley Medical Center

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Tareq Al baghdadi · Principal Investigator

Allegiance Health

Jackson, Michigan, 49201

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Medical Center-Columbus

Novi, Michigan, 48377

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Christopher A. Willner · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Mercy Hospital

Coon Rapids, Minnesota, 55433

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Cancer Center

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Fairview Southdale Hospital

Edina, Minnesota, 55435

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746

Recruiting
Site Public Contact · Contact
218-786-3308
Bret E. Friday · Principal Investigator

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Recruiting
Site Public Contact · Contact
855-776-0015
Antoine Saliba · Principal Investigator

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Regions Hospital

Saint Paul, Minnesota, 55101

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

United Hospital

Saint Paul, Minnesota, 55102

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Essentia Health Sandstone

Sandstone, Minnesota, 55072

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Virginia Clinic

Virginia, Minnesota, 55792

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Golden Triangle

Columbus, Mississippi, 39705

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baptist Cancer Center-Grenada

Grenada, Mississippi, 38901

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Union County

New Albany, Mississippi, 38652

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Oxford

Oxford, Mississippi, 38655

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Desoto

Southhaven, Mississippi, 38671

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Ramzi Abboud · Principal Investigator

Community Hospital of Anaconda

Anaconda, Montana, 59711

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Logan Health Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Community Medical Center

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Nebraska Medicine-Bellevue

Bellevue, Nebraska, 68123

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Michael Haddadin · Principal Investigator

Nebraska Medicine-Village Pointe

Omaha, Nebraska, 68118

Recruiting
Site Public Contact · Contact
402-559-5600
Michael Haddadin · Principal Investigator

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Michael Haddadin · Principal Investigator

OptumCare Cancer Care at Charleston

Las Vegas, Nevada, 89102

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

OptumCare Cancer Care at Fort Apache

Las Vegas, Nevada, 89183

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
James Yoon · Principal Investigator

Cooper Hospital University Medical Center

Camden, New Jersey, 08103

Recruiting
Site Public Contact · Contact
856-325-6757
Michael Brister · Principal Investigator

Saint Barnabas Medical Center

Livingston, New Jersey, 07039

Recruiting
Site Public Contact · Contact
973-322-2934joanne.loeb@rwjbh.org
Neil D. Palmisiano · Principal Investigator

Monmouth Medical Center

Long Branch, New Jersey, 07740

Recruiting
Site Public Contact · Contact
732-923-6564mary.danish@rwjbh.org
Neil D. Palmisiano · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
James Yoon · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
James Yoon · Principal Investigator

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903

Recruiting
Site Public Contact · Contact
732-235-7356
Neil D. Palmisiano · Principal Investigator

The Valley Hospital - Luckow Pavilion

Paramus, New Jersey, 07652

Recruiting
Site Public Contact · Contact
201-634-5792clinicaltrialsresearch@valleyhealth.com
Jason Suh · Principal Investigator

Valley Health System Ridgewood Campus

Ridgewood, New Jersey, 07450

Recruiting
Site Public Contact · Contact
201-634-5792clinicaltrialsresearch@valleyhealth.com
Jason Suh · Principal Investigator

Community Medical Center

Toms River, New Jersey, 08755

Recruiting
Site Public Contact · Contact
732-557-8294Lennette.Gonzales@rwjbh.org
Neil D. Palmisiano · Principal Investigator

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106

Recruiting
Site Public Contact · Contact
505-925-0348HSC-ClinicalTrialInfo@salud.unm.edu
Charles Foucar · Principal Investigator

Roswell Park Cancer Institute

Buffalo, New York, 14263

Recruiting
Site Public Contact · Contact
800-767-9355askroswell@roswellpark.org
Eunice S. Wang · Principal Investigator

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
James Yoon · Principal Investigator

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

Recruiting
Site Public Contact · Contact
212-639-7592
James Yoon · Principal Investigator

Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042

Recruiting
Site Public Contact · Contact
516-734-8896
David Chitty · Principal Investigator

North Shore University Hospital

Manhasset, New York, 11030

Recruiting
Site Public Contact · Contact
516-734-8896
David Chitty · Principal Investigator

Mount Sinai Hospital

New York, New York, 10029

Recruiting
Site Public Contact · Contact
212-824-7309CCTO@mssm.edu
Douglas A. Tremblay · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
James Yoon · Principal Investigator

University of Rochester

Rochester, New York, 14642

Recruiting
Site Public Contact · Contact
585-275-5830
Paul M. Barr · Principal Investigator

Stony Brook University Medical Center

Stony Brook, New York, 11794

Recruiting
Site Public Contact · Contact
800-862-2215
Suhu Liu · Principal Investigator

State University of New York Upstate Medical University

Syracuse, New York, 13210

Recruiting
Site Public Contact · Contact
315-464-5476
Teresa C. Gentile · Principal Investigator

Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Ioannis Mantzaris · Principal Investigator

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
James Yoon · Principal Investigator

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203

Recruiting
Site Public Contact · Contact
800-804-9376
Brittany K. Ragon · Principal Investigator

Duke University Medical Center

Durham, North Carolina, 27710

Recruiting
Site Public Contact · Contact
888-275-3853
Harry P. Erba · Principal Investigator

East Carolina University

Greenville, North Carolina, 27834

Recruiting
Site Public Contact · Contact
252-744-1015eubankss@ecu.edu
Darla K. Liles · Principal Investigator

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157

Recruiting
Site Public Contact · Contact
336-713-6771
Madelyn Burkart · Principal Investigator

Case Western Reserve University

Cleveland, Ohio, 44106

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Rebecca B. Klisovic · Principal Investigator

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Recruiting
Site Public Contact · Contact
800-293-5066Jamesline@osumc.edu
Alice S. Mims · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Manu Pandey · Principal Investigator

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Tareq Al baghdadi · Principal Investigator

Providence Portland Medical Center

Portland, Oregon, 97213

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Charles W. Drescher · Principal Investigator

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Charles W. Drescher · Principal Investigator

Oregon Health and Science University

Portland, Oregon, 97239

Suspended

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Tareq Al baghdadi · Principal Investigator

Geisinger Medical Center

Danville, Pennsylvania, 17822

Recruiting
Site Public Contact · Contact
570-271-5251HemonCCTrials@geisinger.edu
Joseph J. Vadakara · Principal Investigator

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, 17033-0850

Recruiting
Site Public Contact · Contact
717-531-3779CTO@hmc.psu.edu
Joseph Cioccio · Principal Investigator

Lewistown Hospital

Lewistown, Pennsylvania, 17044

Recruiting
Site Public Contact · Contact
717-242-7703HemonCCTrials@geisinger.edu
Joseph J. Vadakara · Principal Investigator

University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, 19104

Recruiting
Site Public Contact · Contact
215-349-8245PMCancerResearch@pennmedicine.upenn.edu
Catherine E. Lai · Principal Investigator

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Chetan S. Jeurkar · Principal Investigator

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-647-8073
Annie P. Im · Principal Investigator

Reading Hospital

West Reading, Pennsylvania, 19611

Recruiting
Site Public Contact · Contact
610-988-9323
Terrence P. Cescon · Principal Investigator

Geisinger Wyoming Valley/Henry Cancer Center

Wilkes-Barre, Pennsylvania, 18711

Recruiting
Site Public Contact · Contact
570-271-5251HemonCCTrials@geisinger.edu
Joseph J. Vadakara · Principal Investigator

Rhode Island Hospital

Providence, Rhode Island, 02903

Recruiting
Site Public Contact · Contact
401-444-1488
John L. Reagan · Principal Investigator

Prisma Health Cancer Institute - Spartanburg

Boiling Springs, South Carolina, 29316

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Easley

Easley, South Carolina, 29640

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Butternut

Greenville, South Carolina, 29605

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Faris

Greenville, South Carolina, 29605

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Eastside

Greenville, South Carolina, 29615

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Greer

Greer, South Carolina, 29650

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Prisma Health Cancer Institute - Seneca

Seneca, South Carolina, 29672

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Suzanne R. Fanning · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Collierville

Collierville, Tennessee, 38017

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

University of Tennessee - Knoxville

Knoxville, Tennessee, 37920

Recruiting
Site Public Contact · Contact
865-544-9773
Clark Cutrer · Principal Investigator

Baptist Memorial Hospital and Cancer Center-Memphis

Memphis, Tennessee, 38120

Recruiting
Site Public Contact · Contact
901-226-1366BCCclintrials@bmhcc.org
Salil Goorha · Principal Investigator

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112

Recruiting
Site Public Contact · Contact
888-424-2100cancerinfo@hci.utah.edu
Paul J. Shami · Principal Investigator

University of Vermont Medical Center

Burlington, Vermont, 05401

Recruiting
Site Public Contact · Contact
802-656-4101rpo@uvm.edu
Diego A. Adrianzen Herrera · Principal Investigator

University of Vermont and State Agricultural College

Burlington, Vermont, 05405

Recruiting
Site Public Contact · Contact
802-656-8990rpo@uvm.edu
Diego A. Adrianzen Herrera · Principal Investigator

University of Virginia Cancer Center

Charlottesville, Virginia, 22908

Recruiting
Site Public Contact · Contact
434-243-6303uvacancertrials@hscmail.mcc.virginia.edu
Daniel R. Reed · Principal Investigator

Inova Schar Cancer Institute

Fairfax, Virginia, 22031

Recruiting
Site Public Contact · Contact
703-720-5210Stephanie.VanBebber@inova.org
Danielle A. Shafer · Principal Investigator

Inova Fairfax Hospital

Falls Church, Virginia, 22042

Recruiting
Site Public Contact · Contact
703-208-6650Stephanie.VanBebber@inova.org
Danielle A. Shafer · Principal Investigator

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

Swedish Medical Center-First Hill

Seattle, Washington, 98122

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

ThedaCare Regional Cancer Center

Appleton, Wisconsin, 54911

Recruiting
Site Public Contact · Contact
920-364-3604ResearchDept@thedacare.org
Yazhini Vallatharasu · Principal Investigator

ThedaCare Regional Medical Center - Appleton

Appleton, Wisconsin, 54911

Recruiting
Site Public Contact · Contact
920-364-3605ResearchDept@thedacare.org
Yazhini Vallatharasu · Principal Investigator

Duluth Clinic Ashland

Ashland, Wisconsin, 54806

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601

Recruiting
Site Public Contact · Contact
608-775-2385cancerctr@gundersenhealth.org
David E. Marinier · Principal Investigator

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Madison, Wisconsin, 53718

Recruiting
Site Public Contact · Contact
800-622-8922clinicaltrials@cancer.wisc.edu
Kieran D. Sahasrabudhe · Principal Investigator

University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792

Recruiting
Site Public Contact · Contact
800-622-8922clinicaltrials@cancer.wisc.edu
Kieran D. Sahasrabudhe · Principal Investigator

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Recruiting
Site Public Contact · Contact
414-805-3666
Guru Subramanian Guru Murthy · Principal Investigator

Marshfield Medical Center-River Region at Stevens Point

Stevens Point, Wisconsin, 54482

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Adedayo A. Onitilo · Principal Investigator

Marshfield Medical Center - Weston

Weston, Wisconsin, 54476

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Adedayo A. Onitilo · Principal Investigator